2Kweon YO, Goodman Z, Dienstag J L, et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies follow ing lamivudine therapy for chronic hepatitis B. J Hepato,2001,35:749.
5Nash K. Telbivudine in the treatment of chronic hepatitis B[J]. Adv Ther, 2009(2) :155 -169.
6Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine inpatients with chronic hepatitis B [ J]. N Engl J Med, 2007(25) :2576 -2588.
7Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivu- dine in Chinesepatients with chronic hepatitis B:resuhs at 1 year of a randomized,double-blind triM[ J]. Hepatology, 2008 (4) :1425.
8Liaw YF, Gane E, Leung N, et al. 2 - Year GLOBE trial re- sults:telbivudine is superior to lamivudine in patients with chronic hepatitisB [ J ]. Gastroenterology, 2009 (2) : 389 - 392.
9Suzuki F. Markers of hepatitis B virus and clinical signifi- cances[ J]. Nihon Rinsho, 2011 (Suppl 4) :385 - 389.
10Fried MW , Piratvisuth T, Lau GK, et al. HBeAg and hepa- titis B virus DNA as outcome predictors during therapy with peginterferon alfa - 2a for HBeAg - positive chronic hepatitis B [ J ]. Hepatology, 2008 (2) :428 - 434.
